Skip to Content


Active Substance: cidofovir
Common Name: cidofovir
ATC Code: J05AB12
Marketing Authorisation Holder: Gilead Sciences International Limited
Active Substance: cidofovir
Status: Withdrawn
Authorisation Date: 1997-04-23
Therapeutic Area: Cytomegalovirus Retinitis
Pharmacotherapeutic Group: Antivirals for systemic use

Therapeutic Indication

Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable.

The marketing authorisation for Vistide has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.